Efficacy of recombinant human brain natriuretic peptide as an adjuvant therapy for severe heart failure, and its impact on oxidative stress and quality of life in patients

Abstract

Purpose: To evaluate the efficacy of recombinant human brain natriuretic peptide as an adjuvant therapy for severe heart failure, and its effect on oxidative stress and quality of life in patients.
 Methods: The study was conducted on 100 patients with severe heart failure who met the screening criteria for this study. They were evenly but randomly divided into two groups. Patients in the control group were given routine treatment (diuretics and cardiac stimulants) for severe heart failure, while the study group received recombinant human brain natriuretic peptide adjuvant therapy in addition to the treatment administered to the control group. Cardiac function, heart rate, oxidative stress indicators, quality of life levels, and adverse drug reactions during treatment were compared before and after treatment.
 Results: After the intervention, the NT-proBNP level in the study group was significantly lower than in the control group while LVEF level was significantly higher than in the control group (p < 0.05). Compared with the control group, the study group showed a significant decrease in heart rate (p < 0.05). The MDA level of the study group was significantly lower than that of the control group while the SOD and GSH-PX levels were significantly higher than those of the control group (p < 0.05). In addition, the GQOLI-74 score of the study group was significantly higher than that of the control group (p < 0.05). Furthermore, there was no statistically significant difference in incidence of adverse reaction between control and study groups (14.0 and 16.0 %, respectively, p < 0.05).
 Conclusion: Recombinant human brain natriuretic peptide has a significant therapeutic effect on severe heart failure, thus improving patients' cardiac function, alleviating their oxidative stress state and enhancing their quality of life, and is also safe.